Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.
ASST Santi Paolo e Carlo, Milan, Italy.
Obes Surg. 2019 Mar;29(3):935-942. doi: 10.1007/s11695-018-3601-5.
Bariatric surgeries such as gastric banding (LAGB), gastric bypass (RYGB), vertical banded gastroplasty (VBG), and sleeve gastrectomy (LSG) decrease body weight in morbid obesity, leading to the resolution of coexisting diabetes mellitus and arterial hypertension in the majority of cases as well as improvements of renal function and liver steatosis. BS (LAGB, RYGB, VBG, and LSG) also reduce incident cases of diabetes, of cardiovascular diseases, and of cancer; these therapeutic and preventive effects on comorbidities of obesity have not been analyzed for malabsorptive surgeries such as biliopancreatic diversion (BPD) or biliointestinal bypass (BIBP). The aim of this study was to analyze the incidence of comorbidities, i.e., diabetes, cardiovascular diseases, and cancer, in obese subjects undergoing BPD and BIBP, in comparison with standard medical treatment of obesity.
Medical records of 1983 obese patients (body mass index (BMI) > 35 kg/m, aged 18-65 years, undergoing surgery (n = 472, of which 111 with diabetes) or medical treatment (n = 1511, of which 422 with diabetes), during the period 1999-2008 (visit 1)) were collected; incident cases of comorbidities were ascertained through December 31, 2016.
Observation period was 12.0 ± 3.48 years (mean ± SD). Compared to non-surgical patients matched for age, body mass index, and blood pressure, malabsorptive surgeries were associated with reduced new incident cases of diabetes (p = 0.001), cardiovascular diseases (p = 0.001), hyperlipidemia (p = 0.001), oculopathy (p = 0.021), and cancer (p = 0.001). The preventive effect of BS was similar in both nondiabetic and diabetic patients for cardiovascular diseases and hyperlipidemia (both p = 0.001). The preventive effect was significant in nondiabetic subjects for coronary heart disease and for cancer, not significant in diabetic subjects.
Patients undergoing malabsorptive bariatric surgery show less incident cases of diabetes, cardiovascular diseases, hyperlipidemia, oculopathy, and cancer than controls receiving medical treatment.
减重手术,如胃束带术(LAGB)、胃旁路术(RYGB)、垂直捆绑胃成形术(VBG)和袖状胃切除术(LSG),可降低病态肥胖患者的体重,在大多数情况下可解决并存的糖尿病和动脉高血压,并改善肾功能和肝脂肪变性。BS(LAGB、RYGB、VBG 和 LSG)还可减少糖尿病、心血管疾病和癌症的新发病例;这些对肥胖合并症的治疗和预防作用尚未在吸收不良手术(如胆胰分流术(BPD)或胆肠旁路术(BIBP)中进行分析。本研究的目的是分析 1983 名肥胖患者(体重指数(BMI)>35kg/m,年龄 18-65 岁,接受手术(n=472,其中 111 例合并糖尿病)或药物治疗(n=1511,其中 422 例合并糖尿病)的合并症(糖尿病、心血管疾病和癌症)发生率,与肥胖的标准药物治疗进行比较。
收集了 1999-2008 年期间(第 1 次就诊)1983 名肥胖患者(BMI>35kg/m,年龄 18-65 岁,接受手术(n=472,其中 111 例合并糖尿病)或药物治疗(n=1511,其中 422 例合并糖尿病)的医疗记录;通过 2016 年 12 月 31 日确定合并症的新发病例。
观察期为 12.0±3.48 年(均值±标准差)。与年龄、体重指数和血压相匹配的非手术患者相比,吸收不良手术与新发糖尿病(p=0.001)、心血管疾病(p=0.001)、高脂血症(p=0.001)、眼病(p=0.021)和癌症(p=0.001)的新发病例减少相关。BS 对非糖尿病和糖尿病患者的心血管疾病和高脂血症的预防作用相似(均为 p=0.001)。BS 对非糖尿病患者的冠心病和癌症具有显著的预防作用,而对糖尿病患者则不显著。
与接受药物治疗的对照组相比,接受吸收不良减重手术的患者新发糖尿病、心血管疾病、高脂血症、眼病和癌症的病例较少。